Posts by: Alice Melão

Alice Melão

October 25, 2019

Durable Responses Seen to ME-401 in Advanced Follicular Lymphoma and CLL/SLL Patients in Ongoing Trial

News

MEI Pharma’s experimental compound ME-401 reduced tumor burden in 78% of patients with relapsed or refractory follicular lymphoma and in 89% of those with relapsed or refractory chronic lymphocytic leukemia or ... Read more

October 22, 2019

Phase 2 Trial Testing Darinaparsin Completes Enrollment of Asian Patients with Relapsed or Refractory PTCL

News

A Phase 2 clinical trial assessing Solasia Pharma’s lead candidate darinaparsin as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL) in Asian patients has reached its target enrollment, ... Read more

October 10, 2019

Copiktra Receives FDA’s Orphan Drug Status for T-cell Lymphoma Treatment

News

The small molecule inhibitor Copiktra (duvelisib) has been given orphan status by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, the therapy’s developer, Verastem Oncology, ... Read more

October 3, 2019

Adcetris Most Effective in Chemo-sensitive Patients, or as Consolidation Therapy After Stem Cell Transplant, Study Finds

News

Treatment with Adcetris (brentuximab vedotin) is most effective in people with relapsed or refractory Hodgkin’s lymphoma who have chemotherapy-sensitive disease, and when used as consolidation therapy immediately after stem cell ... Read more

September 24, 2019

Fate Therapeutics Plans Trials Testing Off-the-shelf NK Cell Therapy for Lymphoma, Leukemia

News

Fate Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to initiate clinical studies evaluating FT596, its off-the-shelf cell-based immunotherapy designed to target multiple tumor proteins. The ... Read more

August 8, 2019September 10, 2019

FDA Asked to Place Abexinostat, Possible Follicular Lymphoma Treatment, on Fast Track

News

Xynomic Pharmaceuticals has filed a request with U.S. Food and Drug Administration (FDA) asking that abexinostat, its lead therapeutic candidate for relapsed or refractory follicular lymphoma, be given fast track designation. The ... Read more

August 6, 2019

Phase 1 Trial of Betalutin, a Radioimmunotherapy, in Advanced DLBCL Now Fully Enrolled

News

The Phase 1 trial evaluating Betalutin — an investigational tumor-targeting antibody labeled with a type of radiation — in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is now fully ... Read more

July 16, 2019

FDA Grants Fast Track Status to Investigational Compound CLR 131 for DLBCL

News

Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, has received fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory diffuse large B-cell ... Read more

July 11, 2019

TG Therapeutics to Seek Accelerated Approval of Umbralisib for Marginal Zone Lymphoma

News

After positive feedback from the U.S. Food and Drug Administration, TG Therapeutics is planning to pursue accelerated approval for umbralisib (TGR-1202) as a treatment for patients with marginal zone lymphoma (MZL). ... Read more

June 28, 2019

X4 Pharmaceuticals, LLS Collaborate to Develop Mavorixafor to Treat Waldenström’s Macroglobulinemia

News

X4 Pharmaceuticals and The Leukemia & Lymphoma Society (LLS) have joined forces to accelerate the development of X4’s lead product candidate, mavorixafor, for the treatment of Waldenström’s macroglobulinemia, a rare ... Read more